1. Early Treatment of Diabetic Retinopathy

3. Diabetic Retinopathy

4. Impact of Diabetes and DR

5. Impact of Diabetes and DR (cont)

6. DR/PDR Risk Factors

7. Hyperglycemia and DR

8. DR Visual Symptoms

9. Recommended Eye Exams for Patients With Diabetes

10. Diabetes Control and Complications Trial (DCCT) Study Design

11. Diabetes Control and Complications Trial (DCCT) Results

12. Epidemiology of Diabetes Interventions and Complications (EDIC)

13. ACCORD Eye Study

14. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Ophthamology Substudy

15. Public Health Recommendations

16. Multidisciplinary Approach

17. PANORAMA Study Design

18. PANORAMA Results

19. PANORAMA Mean Changes in BCVA and CRT

20. PANORAMA VTC or CI-DME Through Week 52

21. PANORAMA Ocular TEAEs Through Week 52

22. VIVID and VISTA Study Design

23. VIVID and VISTA Patients With ≥ 2-Step Improvement in DRSS

24. VIVID and VISTA Post-Hoc Analysis

25. RISE and RIDE Long-Term Open-Label Extension With Ranibizumab

26. Ranibizumab

27. Protocol S Ranibizumab for PDR

28. Protocol S Results

29. Anti-VEGF vs PRP Advantages to Treating NPDR Early

30. Anti-VEGF vs PRP Choosing Which Anti-VEGF to Use

31. Use Imaging to Inform Patients

32. Patient Case 1

33. Patient Case 1 (cont)

34. Patient Case 1 Follow-Up

35. Same-Day Referral to Retina

36. Patient Case 1 Diagnosis

37. Patient Case 1 Diagnosis (cont)

38. Patient Case 1 Diagnosis (cont)

39. Concluding Remarks

40. Abbreviations

41. Abbreviations (cont)